Nome |
# |
Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model, file e27ce42c-c69b-2581-e053-d805fe0acbaa
|
3.905
|
State of play in amyotrophic lateral sclerosis genetics, file e27ce426-f25f-2581-e053-d805fe0acbaa
|
2.351
|
Amyotrophic lateral sclerosis, file e27ce42d-2321-2581-e053-d805fe0acbaa
|
1.734
|
Amyotrophic lateral sclerosis: moving towards a new classification system, file e27ce42b-c9d5-2581-e053-d805fe0acbaa
|
1.618
|
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial, file e27ce42c-af2c-2581-e053-d805fe0acbaa
|
1.317
|
Disease-modifying therapies in amyotrophic lateral sclerosis, file e27ce431-c656-2581-e053-d805fe0acbaa
|
1.299
|
Pain in amyotrophic lateral sclerosis, file e27ce42d-968c-2581-e053-d805fe0acbaa
|
1.049
|
Network Analysis Identifies Disease-Specific Pathways for Parkinson’s Disease, file e27ce42b-a2eb-2581-e053-d805fe0acbaa
|
625
|
Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study, file e27ce427-cd76-2581-e053-d805fe0acbaa
|
621
|
The changing picture of amyotrophic lateral sclerosis: lessons from European registers, file e27ce42b-7da0-2581-e053-d805fe0acbaa
|
581
|
Genome-wide Analyses Identify KIF5A as a Novel ALS Gene, file e27ce42c-62f0-2581-e053-d805fe0acbaa
|
542
|
Multicentre, population-based, case-control study of particulates, combustion products and amyotrophic lateral sclerosis risk, file e27ce42f-2e92-2581-e053-d805fe0acbaa
|
399
|
C9ORF72 intermediate repeat expansion in patients affected by atypical parkinsonian syndromes or Parkinson’s disease complicated by psychosis or dementia in a Sardinian population, file e27ce428-b24a-2581-e053-d805fe0acbaa
|
392
|
Amyotrophic lateral sclerosis and food intake, file e27ce42d-7b57-2581-e053-d805fe0acbaa
|
378
|
CHCH10 mutations in an Italian cohort of familial and sporadic amyotrophic lateral sclerosis patients, file e27ce428-bd7e-2581-e053-d805fe0acbaa
|
336
|
Specialist palliative care improves the quality of life in advanced neurodegenerative disorders: NE-PAL, a pilot randomised controlled study, file e27ce42b-96d5-2581-e053-d805fe0acbaa
|
336
|
The role of arterial blood gas analysis (ABG) in amyotrophic lateral sclerosis respiratory monitoring, file e27ce430-0ec6-2581-e053-d805fe0acbaa
|
321
|
Validation of the revised classification of cognitive and behavioural impairment in ALS, file e27ce430-7b4f-2581-e053-d805fe0acbaa
|
285
|
A Multicentric Prospective Incidence Study of Guillain-Barre Syndrome in Italy. the ITANG Study, file e27ce428-b7be-2581-e053-d805fe0acbaa
|
280
|
NADPH oxidase 2 (NOX2) enzyme activation in patients with chronic inflammatory demyelinating polyneuropathy, file e27ce428-bd81-2581-e053-d805fe0acbaa
|
270
|
Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis, file fc3acdb8-45e9-481c-8767-2ee0fcbf936a
|
270
|
Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis, file 60658d81-4a89-478e-a2cf-743fdda88669
|
252
|
Incidence of amyotrophic lateral sclerosis in the province of Novara, Italy, and possible role of environmental pollution, file e27ce42b-c1ab-2581-e053-d805fe0acbaa
|
248
|
Effect modification of the association between total cigarette smoking and ALS risk by intensity, duration and time-since-quitting: Euro-MOTOR, file e27ce42f-27e0-2581-e053-d805fe0acbaa
|
245
|
Pathogenic VCP mutations induce mitochondrial uncoupling and reduced ATP levels., file e27ce427-db11-2581-e053-d805fe0acbaa
|
243
|
Intraspinal stem cell transplantation for amyotrophic lateral sclerosis: Ready for efficacy clinical trials?, file e27ce42b-88fc-2581-e053-d805fe0acbaa
|
243
|
Projected increase in amyotrophic lateral sclerosis from 2015 to 2040, file e27ce42a-dbfc-2581-e053-d805fe0acbaa
|
240
|
The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease, file e27ce428-b7c2-2581-e053-d805fe0acbaa
|
236
|
Coffee and Amyotrophic Lateral Sclerosis: A Possible Preventive Role, file e27ce42b-aa9e-2581-e053-d805fe0acbaa
|
235
|
G-quadruplex-binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo, file e27ce42c-490d-2581-e053-d805fe0acbaa
|
230
|
Molecular Chaperones in the Pathogenesis of Amyotrophic Lateral Sclerosis: The Role of HSPB1, file e27ce42b-aa9f-2581-e053-d805fe0acbaa
|
227
|
Use of genetic testing in amyotrophic lateral sclerosis by neurologists, file e27ce42b-8d2f-2581-e053-d805fe0acbaa
|
218
|
Alcohol and amyotrophic lateral sclerosis: A possible neuroprotective effect, file e27ce428-bd7b-2581-e053-d805fe0acbaa
|
215
|
Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis, file e27ce433-a050-2581-e053-d805fe0acbaa
|
215
|
MRI signatures of the frontotemporal lobar degeneration continuum, file e27ce428-bd79-2581-e053-d805fe0acbaa
|
214
|
A genome-wide association study of myasthenia gravis, file e27ce428-b818-2581-e053-d805fe0acbaa
|
209
|
Acoustic reflex patterns in amyotrophic lateral sclerosis, file e27ce42d-6c5e-2581-e053-d805fe0acbaa
|
209
|
A20 in Multiple Sclerosis and Parkinson’s Disease: Clue to a Common Dysregulation of Anti-Inflammatory Pathways?, file e27ce42b-919f-2581-e053-d805fe0acbaa
|
206
|
Large Proportion of Amyotrophic Lateral Sclerosis Cases in Sardinia Due to a Single Founder Mutation of the TARDBP Gene, file e27ce426-be58-2581-e053-d805fe0acbaa
|
204
|
ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry, file e27ce42a-7548-2581-e053-d805fe0acbaa
|
204
|
SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis, file e27ce426-ec3d-2581-e053-d805fe0acbaa
|
202
|
null, file e27ce431-6a8b-2581-e053-d805fe0acbaa
|
194
|
Age-related penetrance of the C9orf72 repeat expansion, file e27ce42b-bf10-2581-e053-d805fe0acbaa
|
189
|
ALS mutant FUS proteins are recruited into stress granules in induced pluripotent stem cell-derived motoneurons, file e27ce428-b24d-2581-e053-d805fe0acbaa
|
174
|
The NGS technology for the identification of genes associated with the ALS. A systematic review, file e27ce432-01ed-2581-e053-d805fe0acbaa
|
174
|
C9ORF72 hexanucleotide repeat exerts toxicity in a stable, inducible motor neuronal cell model, which is rescued by partial depletion of Pten, file e27ce42c-069e-2581-e053-d805fe0acbaa
|
172
|
The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients., file e27ce427-0bb0-2581-e053-d805fe0acbaa
|
168
|
The Present and the Future of Neuroimaging in Amyotrophic Lateral Sclerosis, file e27ce426-c972-2581-e053-d805fe0acbaa
|
167
|
Pain in amyotrophic lateral sclerosis, file e27ce42b-81e9-2581-e053-d805fe0acbaa
|
167
|
ATNX2 is not a regulatory gene in Italian amyotrophic lateral sclerosis patients with C9ORF72 GGGGCC expansion, file e27ce42d-613f-2581-e053-d805fe0acbaa
|
167
|
Correlation between Apolipoprotein E genotype and brain metabolism in amyotrophic lateral sclerosis, file e27ce42f-99c9-2581-e053-d805fe0acbaa
|
166
|
The MITOS system predicts long-term survival in amyotrophic lateral sclerosis, file e27ce428-b907-2581-e053-d805fe0acbaa
|
161
|
No evidence for shared genetic basis of common variants in multiple sclerosis and amyotrophic lateral sclerosis, file e27ce426-f25b-2581-e053-d805fe0acbaa
|
160
|
Clinical phenotypes and radiological findings in frontotemporal dementia related to TARDBP mutations, file e27ce427-0553-2581-e053-d805fe0acbaa
|
158
|
Amyotrophic Lateral Sclerosis Incidence and Previous Prescriptions of Drugs for the Nervous System, file e27ce42a-dcfc-2581-e053-d805fe0acbaa
|
156
|
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS, file 9fdbff8d-7026-4818-baba-aaba9bc2ca6f
|
155
|
A Distinct MR Imaging Phenotype in Amyotrophic Lateral Sclerosis: Correlation between T1 Magnetization Transfer Contrast Hyperintensity along the Corticospinal Tract and Diffusion Tensor Imaging Analysis., file e27ce427-d7f1-2581-e053-d805fe0acbaa
|
155
|
Erythropoietin in amyotrophic lateral sclerosis: A multicentre, randomised, double blind, placebo controlled, phase III study, file e27ce428-b250-2581-e053-d805fe0acbaa
|
155
|
A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis, file e27ce42b-0eeb-2581-e053-d805fe0acbaa
|
154
|
Decreased Levels of Foldase and Chaperone Proteins Are Associated with an Early-Onset Amyotrophic Lateral Sclerosis, file e27ce42b-ad28-2581-e053-d805fe0acbaa
|
148
|
Acute, Hemorrhagic, Necrotizing Pancreatitis Associated With Riluzole Treatment in a Patient With Amyotrophic Lateral Sclerosis, file e27ce431-fe16-2581-e053-d805fe0acbaa
|
146
|
Proteostasis and ALS: Protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS), file e27ce42f-2e8f-2581-e053-d805fe0acbaa
|
145
|
Serum C-reactive protein as a prognostic biomarker in amyotrophic lateral sclerosis, file e27ce42d-1597-2581-e053-d805fe0acbaa
|
140
|
The multistep hypothesis of ALS revisited: The role of genetic mutations, file e27ce42d-009a-2581-e053-d805fe0acbaa
|
138
|
A novel p.Ser108LeufsTer15 SOD1 mutation leading to the formation of a premature stop codon in an apparently sporadic ALS patient: insights into the underlying pathomechanisms, file e27ce430-5652-2581-e053-d805fe0acbaa
|
135
|
Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis, file e27ce42d-14fe-2581-e053-d805fe0acbaa
|
132
|
Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial), file e27ce42d-009c-2581-e053-d805fe0acbaa
|
127
|
Interplay between spinal cord and cerebral cortex metabolism in amyotrophic lateral sclerosis, file e27ce42d-3f74-2581-e053-d805fe0acbaa
|
127
|
Professor Camillo Negros Neuropathological Films, file e27ce431-e255-2581-e053-d805fe0acbaa
|
127
|
CHCH10 mutations in an Italian cohort of familial and sporadic amyotrophic lateral sclerosis patients, file e27ce428-bd7f-2581-e053-d805fe0acbaa
|
124
|
Exome array analysis of rare and low frequency variants in amyotrophic lateral sclerosis, file e27ce42f-27e8-2581-e053-d805fe0acbaa
|
116
|
Degenerative neuromuscular diseases: Crucial gene and cell machinery discoveries, file e27ce432-11ae-2581-e053-d805fe0acbaa
|
114
|
Multicenter validation of [18F]-FDG PET and support-vector machine discriminant analysis in automatically classifying patients with amyotrophic lateral sclerosis versus controls, file e27ce42c-b6df-2581-e053-d805fe0acbaa
|
109
|
A Dynamic Bayesian Network model for the simulation of Amyotrophic Lateral Sclerosis progression, file e27ce42f-27e6-2581-e053-d805fe0acbaa
|
102
|
What is the role of the placebo effect for pain relief in neurorehabilitation? Clinical implications from the Italian consensus conference on pain in neurorehabilitation, file e27ce42e-ff96-2581-e053-d805fe0acbaa
|
101
|
Multimodal structural MRI in the diagnosis of motor neuron diseases, file e27ce42c-b94d-2581-e053-d805fe0acbaa
|
100
|
Referral bias in ALS epidemiological studies, file e27ce42c-c699-2581-e053-d805fe0acbaa
|
100
|
NADPH oxidases as drug targets and biomarkers in neurodegenerative diseases: What is the evidence?, file e27ce42c-b94b-2581-e053-d805fe0acbaa
|
99
|
Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials, file e27ce42f-3182-2581-e053-d805fe0acbaa
|
99
|
Lifetime sport practice and brain metabolism in Amyotrophic Lateral Sclerosis, file e27ce431-6901-2581-e053-d805fe0acbaa
|
98
|
C9ORF72 hexanucleotide repeat exerts toxicity in a stable, inducible motor neuronal cell model, which is rescued by partial depletion of Pten, file e27ce42e-d2d5-2581-e053-d805fe0acbaa
|
93
|
Stratification of amyotrophic lateral sclerosis patients: A crowdsourcing approach, file e27ce42f-2e96-2581-e053-d805fe0acbaa
|
93
|
Clinical staging in amyotrophic lateral sclerosis: Analysis of Edaravone Study 19, file e27ce431-a727-2581-e053-d805fe0acbaa
|
89
|
The transcription factor Nurr1 is up-regulated in Amyotrophic Lateral Sclerosis patients and SOD1-G93A mice, file e27ce42f-6469-2581-e053-d805fe0acbaa
|
88
|
Use of multimodal imaging and clinical biomarkers in presymptomatic carriers of C9orf72 repeat expansion, file e27ce431-a704-2581-e053-d805fe0acbaa
|
88
|
Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis, file e27ce42d-9e95-2581-e053-d805fe0acbaa
|
86
|
Cognitive impairment across ALS clinical stages in a population-based cohort, file e27ce430-0a2e-2581-e053-d805fe0acbaa
|
86
|
Comparative analysis of C9Orf72 and sporadic disease in a large multicenter ALS population: The effect of Male sex on survival of C9Orf72 positive patients, file e27ce42f-2f3e-2581-e053-d805fe0acbaa
|
85
|
Tauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis: The TUDCA-ALS trial protocol, file cd0196a5-7b47-4fd2-b577-2f51b7923ffb
|
84
|
Genetic analysis of amyotrophic lateral sclerosis identifies contributing pathways and cell types, file e27ce431-86c6-2581-e053-d805fe0acbaa
|
84
|
Rare Variant Burden Analysis within Enhancers Identifies CAV1 as an ALS Risk Gene, file e27ce431-9972-2581-e053-d805fe0acbaa
|
82
|
Factors predicting survival in ALS: a multicenter Italian study, file e27ce433-7973-2581-e053-d805fe0acbaa
|
82
|
G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial), file e27ce42f-c708-2581-e053-d805fe0acbaa
|
81
|
Protein misfolding, amyotrophic lateral sclerosis and guanabenz: Protocol for a phase II RCT with futility design (ProMISe trial), file e27ce42d-1593-2581-e053-d805fe0acbaa
|
80
|
July 2017 ENCALS statement on edaravone, file e27ce42d-5388-2581-e053-d805fe0acbaa
|
79
|
TRICALS: creating a highway toward a cure, file e27ce431-9a3c-2581-e053-d805fe0acbaa
|
78
|
Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy., file e27ce433-83a1-2581-e053-d805fe0acbaa
|
78
|
Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials, file e27ce42d-1590-2581-e053-d805fe0acbaa
|
77
|
The links between diabetes mellitus and amyotrophic lateral sclerosis, file e27ce431-9973-2581-e053-d805fe0acbaa
|
75
|
Secular trends of amyotrophic lateral sclerosis: The Piemonte and Valle dâAosta register, file e27ce42c-5bf7-2581-e053-d805fe0acbaa
|
74
|
Totale |
30.585 |